Aprea director buys pre-funded, common warrants
Aprea Therapeutics director Richard Peters bought derivative securities linked to the company’s common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aprea Therapeutics director Richard Peters bought derivative securities linked to the company’s common stock. On March 31, 2026, he acquired pre-funded warrants to purchase 123,915 shares of common stock in a private placement, at a purchase price of $0.808 per pre-funded warrant, less the $0.001 exercise price. He also received accompanying common warrants to purchase up to 123,915 additional shares of common stock, with a $0.683 exercise price per share. Both the pre-funded and common warrants are immediately exercisable, but their exercise is limited by a “Beneficial Ownership Limitation” that generally caps common stock ownership at 4.99% of outstanding shares or 9.99% of aggregate voting power. The common warrants will expire on the earlier of December 31, 2029, or 30 calendar days after exercise of the related pre-funded warrants, proportional to the exercised amount.
Insider Trade Summary
Net Buyer: 247,830 shares
Net Buy
2 txns
Insider
Peters Richard
Role
Director
Bought
247,830 shs ($100K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Pre-Funded Warrant | 123,915 | $0.807 | $100K |
| Purchase | Common Warrant | 123,915 | $0.00 | $0.00 |
Holdings After Transaction:
Pre-Funded Warrant — 123,915 contracts (Direct);
Common Warrant — 123,915 contracts (Direct)
Holdings Before and After:
Pre-Funded Warrant, 0 to 123,915 contracts (Direct);
Common Warrant, 0 to 123,915 contracts (Direct)
Footnotes (3)
- F1. On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 123,915 Shares.
- F2. The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation")
- F3. The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise.
Key Figures
Pre-funded warrants purchased: 123,915 warrants
Common warrants issued: 123,915 warrants
Pre-funded warrant purchase price: $0.808 per warrant
+4 more
7 metrics
Pre-funded warrants purchased
123,915 warrants
Private placement closed March 31, 2026
Common warrants issued
123,915 warrants
Accompanying warrants in same transaction
Pre-funded warrant purchase price
$0.808 per warrant
Less $0.001 exercise price per share
Common warrant exercise price
$0.683 per share
Underlying common stock
Ownership limit (shares)
4.99%
Cap on common stock beneficial ownership
Ownership limit (voting power)
9.99%
Cap on combined voting power of securities
Common warrant expiry
December 31, 2029
Or 30 days after pre-funded warrant exercise
Key Terms
Pre-Funded Warrants, Common Warrants, Beneficial Ownership Limitation, accredited investors, +1 more
5 terms
Pre-Funded Warrants financial
"pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 123,915 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Common Warrants financial
"accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 123,915 Shares"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
Beneficial Ownership Limitation regulatory
"would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation")"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
accredited investors financial
"entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
private placement financial
"issued and sold to the Reporting Person in a private placement which closed on March 31, 2026"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aprea Therapeutics (APRE) disclose?
Aprea Therapeutics reported that director Richard Peters bought pre-funded warrants and accompanying common warrants for 123,915 underlying shares each in a private placement that closed on March 31, 2026, giving him new exposure to the company’s common stock.
What prices apply to Aprea Therapeutics (APRE) pre-funded and common warrants?
Each pre-funded warrant was purchased at $0.808, less a $0.001 per-share exercise price. The accompanying common warrants have a $0.683 per-share exercise price. These terms define the effective cost at which the director can acquire Aprea common stock through warrant exercises.
What is the Beneficial Ownership Limitation for APRE’s new warrants?
The warrants include a Beneficial Ownership Limitation preventing exercises that would push the holder above 4.99% of Aprea common shares outstanding or 9.99% of combined voting power, helping limit concentrated ownership and ensuring exercises do not exceed these ownership thresholds.
When do the Aprea Therapeutics (APRE) common warrants expire?
The common warrants are immediately exercisable but will expire on the earlier of December 31, 2029, or 30 calendar days after the related pre-funded warrants are exercised, proportional to the exercised amount, which shortens their life once pre-funded warrants are used.
Was the Aprea Therapeutics (APRE) warrant purchase an open-market trade?
The Form 4 describes a purchase pursuant to a securities purchase agreement with accredited investors, and notes the issuer issued and sold pre-funded and common warrants to the director in a private placement that closed on March 31, 2026, rather than on an exchange.
AI-generated analysis. How Rhea-AI works. Not financial advice.
